Sunshine Biopharma Inc Cash Flow Conversion Efficiency
Sunshine Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has a cash flow conversion efficiency ratio of -0.033x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-917.98K) by net assets ($27.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sunshine Biopharma Inc (2007–2025)
Cash flow conversion efficiency of Sunshine Biopharma Inc from 2007 to 2025. This chart illustrates how Sunshine Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sunshine Biopharma Inc stock quote for real-time trading data and today's change.
Sunshine Biopharma Inc Cash Flow Conversion Ratio Explained
Sunshine Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sunshine Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunshine Biopharma Inc ranked by their cash flow conversion efficiency. Also see how much is Sunshine Biopharma Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Creative Medical Technology Holdings Inc
NASDAQ:CELZ
|
-0.170x |
|
Bri-Chem Corp.
TO:BRY
|
0.008x |
|
Good Shroom Co Inc
V:MUSH
|
-0.642x |
|
Power Line Engineering Public Company Limited
BK:PLE
|
0.243x |
|
Trinitan Metals and Minerals
JK:PURE
|
0.047x |
|
ARGO GOLD INC.
F:P3U
|
0.038x |
|
Birlik Mensucat Ticaret ve Sanayi Isletmesi AS
IS:BRMEN
|
25.838x |
|
GENSOL ENGINEERING ORD (BSE)
NSE:GENSOL
|
0.068x |
Annual Cash Flow Conversion Efficiency for Sunshine Biopharma Inc (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sunshine Biopharma Inc from 2007 to 2025. Review how much free cash does Sunshine Biopharma Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.04 Million | $-5.33 Million | -0.231x | +56.60% |
| 2024-12-31 | $23.50 Million | $-12.53 Million | -0.533x | -28.87% |
| 2023-12-31 | $21.21 Million | $-8.78 Million | -0.414x | -70.51% |
| 2022-12-31 | $21.63 Million | $-5.25 Million | -0.243x | +97.19% |
| 2021-12-31 | $211.66K | $-1.83 Million | -8.642x | -1355.36% |
| 2020-12-31 | $-954.84K | $-657.30K | 0.688x | +2.10% |
| 2019-12-31 | $-735.38K | $-495.80K | 0.674x | -92.67% |
| 2018-12-31 | $-55.75K | $-512.81K | 9.198x | +870.28% |
| 2017-12-31 | $-573.36K | $-543.52K | 0.948x | -36.73% |
| 2016-12-31 | $-209.70K | $-314.18K | 1.498x | +3.10% |
| 2015-12-31 | $-597.04K | $-867.64K | 1.453x | +4.58% |
| 2014-12-31 | $-387.58K | $-538.60K | 1.390x | -98.10% |
| 2013-12-31 | $-7.71K | $-564.40K | 73.203x | +1411.63% |
| 2012-12-31 | $70.43K | $-393.05K | -5.581x | -93.36% |
| 2011-12-31 | $103.00K | $-297.30K | -2.886x | -62.59% |
| 2010-12-31 | $196.22K | $-348.32K | -1.775x | -1597.95% |
| 2009-12-31 | $97.80K | $-10.22K | -0.105x | -108.04% |
| 2008-12-31 | $-17.71K | $-23.03K | 1.301x | +658.01% |
| 2007-12-31 | $13.39K | $-3.12K | -0.233x | -- |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more